CHI St. Luke’s Medical Center has introduced a new RNS treatment system developed by NeuroPace for adults with partial onset seizures diagnosed with epilepsy. The treatment can be applied in patients who are 18 or older, have constant, disabling seizures, and that have not been controlled by two or more medications for the disease.
“This is an incredibly important technological development that we will be using to treat patients with epilepsy for years to come,” said the Associate Professor of Neurology at Baylor College of Medicine, Ian Goldsmith, who is also a member of the Baylor Comprehensive Epilepsy Center. The new treatment uses an advanced technology designed to detect abnormal electrical activity in the brain, through an implantable that delivers responsive neurostimulation by using small levels of electrical stimulation to normalize the brain activity before a seizure.
“We are very excited to be able to offer the RNS System to our patients who have had a difficult time controlling their seizures. We believe this device will have a tremendous impact on helping them lead a more stable life,” added Goldsmith.
Frank Fisher, CEO of the NeuroPace, said that the St. Luke’s Medical Center should be commended “for its resolve to be among the first to make this therapeutic option available to partial onset epilepsy patients.”
The RNS System has not been measured in patients with less frequent seizures, but it has already been demonstrated as safe and effective in epileptics who have an average of three or more disabling seizures per month, during the last three months. It is estimated that the RNS System can benefit approximately 400,000 people in the U.S. — an estimate that CHI St. Luke’s hopes to be on the vanguard of as the technology continues to gain in popularity.